Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3865219 | The Journal of Urology | 2011 | 8 Pages |
Abstract
Consensus has been reached on some of the issues relating to quantifying tumor volume in prostate cancer, such as the lack of utility of substaging pT2 disease. Other questions such as whether to include or subtract intervening benign prostate tissue on prostate needle cores will require additional studies. Finally, matters such as the need to quantify cancer at radical prostatectomy or which method of quantifying cancer on needle biopsy is superior will likely remain contentious due to the close interrelationship and redundancy of prognostic variables.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Jonathan I. Epstein,